Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
- Funding
- Amount varies
- Deadline
- January 7, 2028
- Who can apply
- State governments, County governments, City or township governments +11 more
Description
The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and state-controlled colleges and universities
- Federally recognized Native American tribal governments
- Public and Indian housing authorities
- Other Native American tribal organizations
- Nonprofits with 501(c)(3) status
- Nonprofits without 501(c)(3) status
- Private colleges and universities
- For-profit organizations (other than small businesses)
- Small businesses
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Industry Tags
About This Grant
The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.
Funding Information
Eligibility Overview
Eligible applicants include: State governments, County governments, City or township governments +11 more. Always confirm on the official listing.
Eligibility requirements vary by opportunity. Always review the official listing before investing time in an application.
How to Apply
- 1
Review the full opportunity
Read the complete Notice of Funding Opportunity (NOFO) for this National Institutes of Health program on its official page (https://www.grants.gov/search-results-detail/357015).
- 2
Confirm eligibility
Check that your organization meets every requirement set by National Institutes of Health — applicant type, location, registration status, and any prior-award restrictions.
- 3
Prepare required documents
Gather your budget narrative, needs statement, organizational details, SAM.gov registration, and any required certifications.
- 4
Submit before the deadline
This opportunity closes on January 7, 2028. Submit well before the deadline to leave time for fixes.
Grant Writing Tips
General tips for preparing your application:
- ✓Start early: registration and review steps take time.
- ✓Match your needs statement to the funder's stated priorities.
- ✓Have someone outside your team check the budget narrative.
More Grants from National Institutes of Health
- Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) →
- NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32) →
- Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) →
- View all 356 grants from NIH →
Frequently Asked Questions
Who is eligible for Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)?
Eligible applicants include: State governments, County governments, City or township governments +11 more. Always confirm on the official listing.
How much funding does Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) provide?
An award amount is not stated in the listing for Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional). See the official grant page for funding details.
When is the deadline for Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)?
The application deadline for Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) is January 7, 2028. Submit well before the deadline to leave time for fixes.
How do I apply for Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)?
Apply for Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) through the official grant page (https://www.grants.gov/search-results-detail/357015). Confirm your eligibility and prepare your application materials before the deadline.
Helpful Resources
Need help writing your grant application?
Try Instrumentl — Grant Writing Software →GrantLocate may earn a commission from qualifying purchases. This does not affect our grant listings.